Kailash Mosalpuria
Hematology & Oncology · Lincoln, NENPI 1669636643
Payments from drug & device makers
Across 556 payments — averaging $7605.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.6M
- AbbVie$734K
- AstraZeneca$598K
- Pfizer$503K
- G1 Therapeutics, Inc.$261K
- Biontech SE$248K
- plus $278K from 41 others
Across 6 payments — averaging $187.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$902
- AbbVie$222
What the payments were for
- Consulting fees$11,77069%
- Speaking & faculty fees$2,21313%
- Travel & lodging$7715%
- Food & beverage$1,96512%
- Education$3692%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,228,533 in reported general payments places this provider in the 95th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 88 | $1,468,269 |
| PomalystPomalidomide | 53 | $1,002,103 |
| Lenalidomide | 73 | $912,704 |
| CalquenceAcalabrutinib Maleate | 53 | $782,690 |
| RevlimidLenalidomide | 38 | $605,666 |
| NubeqaDarolutamide | 27 | $363,103 |
| NinlaroIxazomib Citrate | 28 | $358,155 |
| VenclextaVenetoclax | 28 | $355,211 |
| BrukinsaZanubrutinib | 13 | $195,081 |
| XtandiEnzalutamide | 12 | $161,029 |
| EliquisApixaban | 38 | $27,047 |
| Abiraterone Acetate | 25 | $25,195 |
| XareltoRivaroxaban | 31 | $22,570 |
| Imatinib Mesylate | 24 | $21,817 |
| Enoxaparin Sodium | 12 | $4,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $118 | $1,468,26988 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $10,554 | $1,002,10353 claims |
| AstraZenecaCalquence | $597,964 | $782,69053 claims |
| Bristol Myers SquibbRevlimid | $45,647 | $605,66638 claims |
| BayerNubeqa | $14 | $363,10327 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $31 | $358,15528 claims |
| AbbVieVenclexta | $733,861 | $355,21128 claims |
| Astellas Pharma US IncXtandi | $335 | $161,02912 claims |
| PfizerEliquis | $503,386 | $27,04738 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $31 | $25,19525 claims |
| Johnson & JohnsonXarelto | $150 | $22,57031 claims |
| Lilly USA, LLCOlanzapine | $28 | $6529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Lincoln
- Madhu MidathadaLincoln$1.1M
- Mark HutchinsLincoln$1.1M
- Eric AveryLincoln$1.1M
- Steven DunderLincoln$612K
- Stacey KnoxLincoln$573K
- Alan BergLincoln$396K
- Joni TilfordLincoln$181K
- Nathan GreenLincoln$136K
- Scott McHamLincoln$33K
- Melissa CetakLincoln$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.